Research Article
Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
Table 4
RAVs to nucleoside/nucleotide analogue NS5B inhibitors.
| | Resistance mutations | Drugs | Reference | Detected resistance mutations | Detected resistance mutations |
| | Case number | | | | | | A15G | PSI-352938 + PSI-353661 | [15] | A15G 2.3% (2/88) | — | | A15S | PSI-352938 + PSI-353661 | [15] | — | — | | S96T | Sofosbuvir + mericitabine | [33] | S96T 1.1% (1/88) | — | | Case number | | | | | | C223H | Sofosbuvir + mericitabine | [33] | — | — | | S282T | Sofosbuvir + mericitabine | [33] | S282T 20.7% (17/82) | — | | V321I | PSI-352938 + PSI-353661 | [15] | — | — |
|
|
